Compounders Research Compare

ProKidney Corp.(PROK)

Biotechnology · Winston-Salem, NC

$1.60+0.01 (+0.95%)

Delayed quote: Oct 6, 2026, 3:00 PM EDT

About ProKidney Corp.

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

Winston-Salem, NC

231 employees

www.prokidney.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Bruce Culleton

View full financials

Earnings Yield: N/A

Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The earnings yield is N/A as of 2026-10-06T19:03:05.210Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:03:05.210Z.

Quote observation: 2026-10-06T19:00:04.000Z. Amounts in USD. The price header may show a later quote.

Unrounded diluted TTM EPS · period ending 2026-06-30: -0.57
Quote price: 1.595

FMP input reference: 5f06b8b41e0980caada53469fccf6de542fb6b04de3a821a907ddebd40a39f21

P/E Ratio|FCF Yield|Dividend Yield|All Metrics

PROK Earnings Yield Metrics

EARNINGS YIELD

N/A

PROK Competitors' Earnings Yield

ProKidney Corp.

Current

Market Cap

$536.32M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Nuvectis Pharma, Inc.

Market Cap

$534.18M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Delcath Systems, Inc.

Market Cap

$535.43M

Earnings Yield

0.08%

TTM Avg

0.28%

3Y Avg

0.28%

5Y Avg

0.28%

Shattuck Labs, Inc.

Market Cap

$543.80M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Phathom Pharmaceuticals, Inc.

Market Cap

$542.44M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Monopar Therapeutics Inc.

Market Cap

$548.99M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Immix Biopharma, Inc.

Market Cap

$526.07M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aclaris Therapeutics, Inc.

Market Cap

$523.04M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Altimmune, Inc.

Market Cap

$522.16M

Earnings Yield

N/A

TTM Avg

516.44%

3Y Avg

516.44%

5Y Avg

516.44%

BlossomHill Therapeutics, Inc.

Market Cap

$520.33M

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
ProKidney Corp. (PROK)	$536.32M	N/A	N/A	N/A	N/A
Nuvectis Pharma, Inc. (NVCT)vs ›	$534.18M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$535.43M	0.08%	0.28%	0.28%	0.28%
Shattuck Labs, Inc. (STTK)vs ›	$543.80M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$542.44M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$548.99M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$526.07M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$523.04M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$522.16M	N/A	516.44%	516.44%	516.44%
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$520.33M	N/A	N/A	N/A	N/A

Earnings Yield vs P/E Ratio

Earnings Yield

N/A

EPS ÷ Price

P/E Ratio

N/A

Price ÷ EPS

Formula: Earnings Yield = (EPS / Price) × 100

Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.

How earnings yield is used:

It expresses earnings relative to share price as a percentage
It can be compared with FCF yield and dividend yield
It can be compared with bond yields because both are percentages
It is mathematically the inverse of the P/E ratio

Earnings Yield Formula & Definition

Earnings Yield = EPS (TTM) / Share Price

Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Yield Dividend Yield All Metrics